Inflarx N.V. (IFRX)
NASDAQ:IFRX
Top Page
InflaRx
(NASDAQ:IFRX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.92
▼(-7.90% Downside)
Action:ReiteratedDate:03/21/26
The score is held down primarily by weak financial performance (minimal revenue, sizable ongoing losses, and persistent cash burn). Technicals are roughly neutral with limited momentum, while valuation metrics offer little support due to losses and no indicated dividend yield.
Positive Factors
Strategic focus on izicopan
Management’s explicit strategic pivot to concentrate resources on izicopan centralizes R&D spend and simplifies portfolio priorities. By reallocating capital toward a single lead oral C5aR program and planning Phase 2b work, the company improves capital efficiency, tightens execution focus, and increases the chance of reaching a meaningful proof-of-concept within the next 6–18 months, making milestone-driven value creation more achievable.
Negative Factors
Persistent cash burn
The company continues to generate negative operating and free cash flow, improving only modestly year-over-year. Sustained cash burn necessitates either equity raises, partnerships, or further cost cuts to fund clinical programs. This structural cash dependency increases dilution risk and constrains strategic optionality over the next 2–6 quarters unless milestones trigger external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic focus on izicopan
Management’s explicit strategic pivot to concentrate resources on izicopan centralizes R&D spend and simplifies portfolio priorities. By reallocating capital toward a single lead oral C5aR program and planning Phase 2b work, the company improves capital efficiency, tightens execution focus, and increases the chance of reaching a meaningful proof-of-concept within the next 6–18 months, making milestone-driven value creation more achievable.
Read all positive factors
InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$72.29M
Dividend YieldN/A
Average Volume (3M)382.93K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding72,292,860
10 Day Avg. Volume476,591
30 Day Avg. Volume382,933
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.39
Price to Sales (P/S)2053.09
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue1.80K
Enterprise Value/Gross Profit-6.88
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$7.33Price Target Upside633.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$13.83K
InflaRx Business Overview & Revenue Model
Company Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a var...
How the Company Makes Money
InflaRx is a clinical-stage company and, based on publicly available information, it has not established a broad, recurring revenue base from marketed products. Its potential and/or historical sources of cash and revenue typically include: (1) col...
InflaRx Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.17K | 165.79K | 63.09K | 0.00 | 0.00 |
| Gross Profit | -7.36M | -3.15M | -469.17K | -627.01K | -791.26K |
| EBITDA | -48.50M | -45.55M | -42.06M | -30.31M | -53.11M |
| Net Income | -43.83M | -46.06M | -42.67M | -30.99M | -53.93M |
Balance Sheet | |||||
| Total Assets | 55.19M | 76.02M | 120.21M | 102.40M | 125.14M |
| Cash, Cash Equivalents and Short-Term Investments | 46.44M | 18.38M | 12.77M | 81.81M | 83.41M |
| Total Debt | 897.53K | 805.09K | 1.12M | 1.36M | 1.43M |
| Total Liabilities | 13.65M | 14.60M | 17.63M | 14.05M | 19.86M |
| Stockholders Equity | 41.54M | 61.42M | 102.58M | 88.35M | 105.28M |
Cash Flow | |||||
| Free Cash Flow | -34.03M | -48.60M | -37.89M | -33.91M | -39.97M |
| Operating Cash Flow | -33.92M | -48.56M | -37.81M | -33.74M | -39.94M |
| Investing Cash Flow | 3.11M | 52.36M | -17.70M | 19.36M | -25.95M |
| Financing Cash Flow | 32.00M | 386.45K | 52.99M | 1.94M | 61.58M |
InflaRx Technical Analysis
Positive
1.00
Price Trends
0.92
Positive
1.00
Positive
1.08
Negative
Market Momentum
0.02
Negative
63.02
Neutral
86.90
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Positive. The current price of 1 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.92, and below the 200-day MA of 1.08, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 63.02 is Neutral, neither overbought nor oversold. The STOCH value of 86.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IFRX.
InflaRx Risk Analysis
InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InflaRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $142.78M | 1.57 | 43.14% | ― | ― | 814.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $71.97M | -2.21 | 240.83% | ― | -49.17% | 23.37% | |
46 Neutral | $72.29M | -1.32 | -81.77% | ― | ― | ― | |
42 Neutral | $38.03M | -16.66 | -79.12% | ― | 51.27% | ― | |
| ― | $90.19M | -9.85 | -65.55% | ― | ― | 11.78% | |
45 Neutral | $178.37M | -1.27 | -97.41% | ― | ― | -60.99% |
* Healthcare Sector Average
IFRX
InflaRx
1.07
-0.03
-2.73%
ORMP
Oramed Pharm
3.79
1.71
82.39%
ATRA
Atara Biotherapeutics
4.89
-1.09
-18.23%
ANIX
Anixa Biosciences
2.85
0.00
0.00%
CLNN
Clene
6.48
3.41
111.07%
ABOS
Acumen Pharmaceuticals
2.51
1.46
139.05%
InflaRx Corporate Events
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
Mar 19, 2026
On March 19, 2026, InflaRx reported its full-year 2025 results and outlined a strategic pivot to focus on izicopan after promising Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, with Phase 2b planning in HS underway a...
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
Jan 8, 2026
On January 8, 2026, InflaRx announced a strategic realignment that sharply prioritizes the development of its oral C5aR inhibitor izicopan in hidradenitis suppurativa and other inflammation and immunology indications, supported by plans for a Phas...
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
Dec 30, 2025
On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative skin disease, following the trial’s early termination earlier in 2025 after an independ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.